North America Latent TB Detection Market is witnessing steady growth driven by increasing efforts to eliminate tuberculosis, rising awareness of early disease screening, and growing adoption of advanced diagnostic technologies. The region benefits from well-established healthcare infrastructure, strong public health initiatives, and increasing investments in infectious disease surveillance and laboratory diagnostics.

Global Latent TB Detection Market Trends are gaining momentum as governments, healthcare providers, and diagnostic manufacturers focus on expanding access to reliable tuberculosis screening. According to The Insight Partners, The sector was valued at US$ 1.23 billion in 2021 and is projected to reach US$ 2.00 billion by 2031, registering a CAGR of 5.8% during the forecast period from 2024 to 2031. Increasing adoption of interferon gamma release assays (IGRA), supportive public health initiatives, and greater awareness regarding latent tuberculosis infection are contributing to sustained industry expansion.

Get Sample PDF @ https://www.theinsightpartners.com/sample/TIPRE00014239

Rising Burden of Tuberculosis Accelerates Diagnostic Demand

The increasing prevalence of tuberculosis remains the primary factor supporting growth across the latent TB detection industry. According to global health estimates, nearly 10 million people develop tuberculosis annually, while more than one million deaths are attributed to the disease each year. Countries across Asia Pacific, particularly India and Indonesia, continue to experience a substantial disease burden, encouraging broader implementation of screening initiatives.

Healthcare systems are placing greater emphasis on identifying latent infections before they progress into active tuberculosis. Early diagnosis enables timely preventive treatment, reducing disease transmission while improving long-term patient outcomes. This preventive healthcare approach is becoming an essential component of national tuberculosis elimination strategies.

Technological Advancements Reshape Diagnostic Landscape

Innovation continues to transform latent tuberculosis detection through the introduction of highly sensitive and specific diagnostic technologies. Among available testing methods, Interferon Gamma Release Assays (IGRA) have gained significant popularity due to their improved diagnostic accuracy compared with traditional Tuberculin Skin Tests (TST).

Manufacturers are introducing advanced blood-based assays capable of delivering dependable results with minimal patient inconvenience. Continued investments in molecular diagnostics, rapid laboratory technologies, and automated testing platforms are further enhancing efficiency across hospitals and diagnostic laboratories.

Research collaborations between biotechnology companies and public health organizations are also supporting the commercialization of next generation tuberculosis diagnostic solutions that improve testing accessibility while reducing turnaround times.

Government Initiatives Strengthen Industry Expansion

Public health policies remain one of the strongest growth catalysts across the latent TB detection sector. Governments worldwide continue investing in national tuberculosis elimination programs, screening campaigns, and diagnostic infrastructure.

Several countries have introduced free tuberculosis testing programs, expanded laboratory networks, and improved access to preventive treatment services. India's National Strategic Plan for Tuberculosis Elimination and similar initiatives across Southeast Asia demonstrate increasing commitment toward controlling latent tuberculosis infections.

Healthcare organizations are also updating tuberculosis screening recommendations for healthcare workers and high-risk populations. These regulatory developments continue to increase demand for reliable screening products across hospitals, laboratories, and diagnostic centers.

Segment Analysis Highlights Emerging Opportunities

Based on test type, the industry is segmented into:

  • Tuberculin Skin Test (TST)
  • Interferon Gamma Release Assay (IGRA)

The IGRA segment accounts for the largest share and is expected to maintain the highest growth rate throughout the forecast period due to its superior specificity, particularly among vaccinated populations.

By end user, the industry includes:

  • Hospitals
  • Diagnostic Centers
  • Laboratories
  • Others

Hospitals currently represent the leading end-user segment owing to higher patient volumes, integrated laboratory capabilities, and comprehensive tuberculosis management programs. Diagnostic centers and specialized laboratories are also witnessing increased adoption as outsourced diagnostic services continue to expand.

Regional Outlook and Competitive Landscape

North America continues to maintain a strong position due to established healthcare infrastructure, favorable screening guidelines, and widespread adoption of advanced diagnostic technologies. Europe also demonstrates consistent growth through comprehensive infectious disease surveillance programs.

Asia Pacific is expected to register the fastest growth during the forecast period. Rising tuberculosis incidence, expanding healthcare expenditure, and government-supported elimination campaigns are driving widespread adoption of latent TB detection solutions across China, India, and other developing economies. Growing awareness regarding preventive healthcare further supports regional expansion.

Leading companies continue investing in product innovation, strategic collaborations, regulatory approvals, and geographic expansion to strengthen their competitive positions.

Key Players

  • QIAGEN
  • bioMérieux S.A.
  • F. Hoffmann La Roche Ltd.
  • BD
  • ARKRAY, Inc.
  • Abbott
  • Serum Institute of India Pvt. Ltd.
  • Oxford Immunotec Ltd.
  • Lionex GmbH

Future Outlook

The future of the global latent TB detection industry appears promising as healthcare systems increasingly prioritize early diagnosis and preventive disease management. Continued advancements in IGRA technology, expansion of government-funded screening programs, and growing investment in diagnostic infrastructure are expected to sustain long-term growth. With Asia Pacific emerging as the fastest expanding region and innovation improving testing accuracy and accessibility, the industry is well positioned to play a critical role in global tuberculosis elimination efforts through 2031.

Related Report:

1) Procedure Trays Market Overview and Growth by 2031

2) Embolization Coils Market Size, Share, and Forecast 2025-2031

3) Aortic Valve Replacement Devices Market Growth and Recent Trends by 2030

About Us -

The Insight Partners provides comprehensive syndicated and tailored market research services in the healthcare, technology, and industrial domains. Renowned for delivering strategic intelligence and practical insights, the firm empowers businesses to remain competitive in ever-evolving global markets.

Contact Us:
Ankit Mathur | The Insight Partners
E-mail: ankit.mathur@theinsightpartners.com
Phone: +1-646-491-9876

Also Available in : Korean German Japanese French Chinese Italian Spanish